Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

• Drug: PF-03463275
  
  Oral single 20 mg dose as two 10mg controlled release tablets
• Drug: PF-03463275
  
  Oral single 40 mg dose as four 10mg controlled release tablets
• Drug: PF-03463275
  
  Oral single 60 mg dose as six 10mg controlled release tablets
  Other Name: Not Specified
• Drug: Placebo
  
  Oral single dose as matching placebo
• Drug: PF-03463275
  
  Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
  Other Name: Not Specified
• Drug: Placebo
  
  Oral multiple doses as matching placebo for 7 days

• Experimental: Single dose
  
  Interventions:
  

  • Drug: PF-03463275
  • Drug: PF-03463275
  • Drug: PF-03463275
  • Drug: Placebo
• Experimental: Multiple dose
  
  Interventions:
  

  • Drug: PF-03463275
  • Drug: Placebo

Inclusion Criteria:

• Healthy male subjects between the ages of 18 and 55 years.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight >50 kg (110 lbs).
• Japanese subjects must have four Japanese grandparents who were born in Japan.

Exclusion Criteria:

• Subjects that are genotyped to be PM (poor metabolizer), UM (ultrarapid metabolizer), IM/EM and EM/UM for CYP2D6 status.
• Evidence or history of clinically significant hematological (including anemia), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).